PDF   Print   View All
March 20, 2003
HEMISPHERX BIOPHARMA TO PRESENT AT THE STRATEGIC RESEARHC INTSTITUTES FIRST 'siRNA' CONFERENCE
Conference To Be Held March 24-25, 2003 At Hilton La Jolla, California


Philadelphia, PA, Thursday, March 20, 2003: Hemispherx Biopharma (AMEX: HEB) announced today that its Vice President of Medical Affairs, Dr. David R. Strayer, M.D., will present at the Strategic Research Institutes first International ‘siRNA (standing for Small Interfering RNA’s) in Drug Discovery and Development Conference’ at the Hilton La Jolla Torrey Pines, La Jolla, CA. Dr. Strayer will present on Tuesday, March 25, 2003 at 10:45 a.m. on “Clinical Development of Specifically Configured Double-Stranded RNA Therapeutic (Ampligen)”

The Institute’s first International ‘siRNA in Drug Discovery and Development Conference’ will gather the opinions of siRNA related companies, large and small, regarding business development, strategic relationships, transactions, market trends and prospects as well as the latest technology developments. Speakers in addition to Dr. Strayer will include individuals representing companies such as Amgen, Inc., Aventis Pharmaceuticals, Isis Pharmaceuticals, Johnson & Johnson, Merck & Co., Millennium Pharmaceuticals, Inc. and Pfizer, Inc.

RNA is typically used to neutralize or shut off bad genes, as those causing cancer or viral proliferation, such as AIDS and Hepatitis C viruses. In contrast, Hemispherx uses RNA to switch on, or augment, immune activators to actually enhance natural defenses. The augmentation of the gene product Interferon, IFN, can result in higher cure rates in chronic viral diseases. Last week, Hemispherx acquired a full commercialized natural IFN drug, Alferon-N, with which it will apply its therapeutic concept to increase cures. The name of the Company’s lead product, Ampligen, is derived from the phrase “Amplify…genes.”

ABOUT HEMISPHERX
Hemispherx Biopharma is a biopharmaceutical company focusing on the development of nucleic acids to enhance anti-viral defense systems. Its lead compound, a specifically configured double-stranded RNA, Ampligen, is in Phase II-III clinical development for immune-based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome. Preclinical studies have shown that Ampligen has anti-viral activities against a broad spectrum of viruses. Other drug candidates in our anti-viral pipeline include small molecular weight RNAs denoted Oragens. The Oragens also offer the potential of a broad anti-viral spectrum by activation of an intracellular antiviral enzyme cascade. For more information, you can visit the corporate website at www.Hemispherx.net.


ABOUT siRNA
Small interfering RNAs (siRNAs) have gained a lot of attention in drug discovery and development due to their powerful ability in selective gene silencing. As a promising technology it's critical and never too early to discuss and address the business aspects, in addition to the latest technology developments.


Contact(s):
Hemispherx Biopharma, Inc., Investor Relations
Dianne Will
(518) 398-6222, Fax: (518) 398-6223

Robert Giordano, MRB Investor Relations
(212) 495-0200, Fax: (212) 495-0746

HEB's Web Site: www.hemispherx.net


Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including AmpligenÒ and Oragensä) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic AlferonÒ do not imply that the product will be specifically approved commercially for these other treatment indications.